Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Tassi

Showing results (41-50 of 49) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 49 results.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|October 27, 2011
Serum human epididymis protein 4 and risk for ovarian malignancy algorithm as new diagnostic and prognostic tools for epithelial ovarian cancer managementElisabetta Bandiera, Chiara Romani, Claudia Specchia, et al.
British Journal of Cancer|April 7, 2011
Diagnostic and prognostic impact of serum HE4 detection in endometrial carcinoma patientsE Bignotti, M Ragnoli, L Zanotti, et al.
Clinical Chemistry and Laboratory Medicine|October 26, 2012
Human epididymis protein 4 as a serum marker for diagnosis of endometrial carcinoma and prediction of clinical outcomeLaura Zanotti, Eliana Bignotti, Stefano Calza, et al.
European Journal of Cancer (Oxford, England : 1990)|January 12, 2010
Trop-2 overexpression as an independent marker for poor overall survival in ovarian carcinoma patientsEliana Bignotti, Paola Todeschini, Stefano Calza, et al.
BMC Cancer|July 29, 2009
Mammaglobin B is an independent prognostic marker in epithelial ovarian cancer and its expression is associated with reduced risk of disease recurrenceRenata A Tassi, Stefano Calza, Antonella Ravaggi, et al.
BMC Clinical Pathology|November 16, 2012
Trop-2 protein overexpression is an independent marker for predicting disease recurrence in endometrioid endometrial carcinomaEliana Bignotti, Laura Zanotti, Stefano Calza, et al.
Journal of Translational Medicine|July 4, 2013
Secretoglobin expression in ovarian carcinoma: lipophilin B gene upregulation as an independent marker of better prognosisEliana Bignotti, Renata A Tassi, Stefano Calza, et al.
Journal of Experimental & Clinical Cancer Research : CR|May 10, 2017
FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patientsRenata A Tassi, Paola Todeschini, Eric R Siegel, et al.
Oncogene|December 6, 2011
A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancerE S Ratner, F K Keane, R Lindner, et al.
Pageof 5

Showing results (41-50 of 49) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 49 results.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|October 27, 2011
Serum human epididymis protein 4 and risk for ovarian malignancy algorithm as new diagnostic and prognostic tools for epithelial ovarian cancer managementElisabetta Bandiera, Chiara Romani, Claudia Specchia, et al.
British Journal of Cancer|April 7, 2011
Diagnostic and prognostic impact of serum HE4 detection in endometrial carcinoma patientsE Bignotti, M Ragnoli, L Zanotti, et al.
Clinical Chemistry and Laboratory Medicine|October 26, 2012
Human epididymis protein 4 as a serum marker for diagnosis of endometrial carcinoma and prediction of clinical outcomeLaura Zanotti, Eliana Bignotti, Stefano Calza, et al.
European Journal of Cancer (Oxford, England : 1990)|January 12, 2010
Trop-2 overexpression as an independent marker for poor overall survival in ovarian carcinoma patientsEliana Bignotti, Paola Todeschini, Stefano Calza, et al.
BMC Cancer|July 29, 2009
Mammaglobin B is an independent prognostic marker in epithelial ovarian cancer and its expression is associated with reduced risk of disease recurrenceRenata A Tassi, Stefano Calza, Antonella Ravaggi, et al.
BMC Clinical Pathology|November 16, 2012
Trop-2 protein overexpression is an independent marker for predicting disease recurrence in endometrioid endometrial carcinomaEliana Bignotti, Laura Zanotti, Stefano Calza, et al.
Journal of Translational Medicine|July 4, 2013
Secretoglobin expression in ovarian carcinoma: lipophilin B gene upregulation as an independent marker of better prognosisEliana Bignotti, Renata A Tassi, Stefano Calza, et al.
Journal of Experimental & Clinical Cancer Research : CR|May 10, 2017
FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patientsRenata A Tassi, Paola Todeschini, Eric R Siegel, et al.
Oncogene|December 6, 2011
A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancerE S Ratner, F K Keane, R Lindner, et al.
Pageof 5